If approved, Dupixent would become the first and only targeted treatment for BP ... Sanofi and Regeneron’s Dupixent sBLA for bullous pemphigoid" was originally created and published by ...

Please check back soon for updates. The supplemental biologics license application for Dupixent for the treatment of bullous pemphigoid in adults has been accepted by the FDA for priority review ...

Moreover, current treatment options can be challenging for this primarily elderly patient population because they work by suppressing their immune system. By targeting the underlying type 2 ...

Dupilumab has been accepted for priority review by the US Food and Drug Administration (FDA) for the treatment of bullous pemphigoid (BP) in adults, according to a press release from the ...

First up is the ADEPT study in bullous pemphigoid (BP), a rare skin condition ... with no relapse, and standard treatment with oral corticosteroids had been tailed off without the need for any ...

Autoantibodies to IgG and IgG4 appear to be the most common findings observed on direct immunofluorescent testing in patients with mucous membrane pemphigoid. Treatment for mucous membrane ...

The table is a review of notable updates that occurred in February 2025 for investigational products in development.

“People with bullous pemphigoid live with unrelenting itch, blisters and painful lesions that can be debilitating and make it difficult to function daily. Moreover, current treatment options can be ...

BLA accepted for review Dupilumab (Regeneron and Sanofi) Interleukin-4 receptor alpha antagonist Treatment of adults with bullous pemphigoid. sBLA accepted for Priority Review Rezpegaldesleukin ...

During treatment, all patients underwent a protocol ... Proportion of patients achieving ≥90% reduction in Bullous Pemphigoid Disease Area Index (scale: 0-360) Proportion of patients with ...